<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511717</url>
  </required_header>
  <id_info>
    <org_study_id>106903</org_study_id>
    <nct_id>NCT02511717</nct_id>
  </id_info>
  <brief_title>A Trial of Transcutaneous Nerve Stimulation for OAB</brief_title>
  <official_title>A Randomized Trial of Transcutaneous Nerve Stimulation for Overactive Bladder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overactive bladder causes urinary frequency, urgency and in some cases urgency incontinence.
      This study is testing the efficacy of transcutaneous tibial nerve stimulation (using skin
      patch electrodes via a transcutaneous electrical nerve stimulation (TENS) machine) for the
      treatment of women with clinical symptoms of overactive bladder.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient reported outcome measure (Patient percention of bladder condition question)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient percention of bladder condition (PPBC) question</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overactive bladder questionnaire short form (OAB-q SF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>OAB quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voiding diary</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24hr pad weights</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician assessment of treatment benefit</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcutaneous nerve stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcutaneous tibial nerve stimulation</intervention_name>
    <description>Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.</description>
    <arm_group_label>Transcutaneous nerve stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham transcutaneous tibial nerve stimulation</intervention_name>
    <description>Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, &gt;18 years of age, with the clinical diagnosis of overactive bladder.

          2. Failure of behavioral measures and pharmacologic therapy to adequately control
             overactive bladder symptoms.

          3. Baseline patient perception of bladder condition score of 2 or higher.

        Exclusion Criteria:

          1. Current or previous percutaneous or sacral neuromodulation therapy

          2. Stress predominant urinary incontinence

          3. Newly added bladder medication or dose change with the last 2 months (Tamsulosin,
             Silodosin, Alfuzosin, Terazosin, Baclofen, Diazepam, amitriptyline, imipramine, DDAVP,
             tolterodine, oxybutynin, fesoterodine, darifenacin, solifenacin, trospium, mirabegron)

          4. Intravesical botulinum toxin use within the last 1 year

          5. Implanted pacemaker or defibrillator

          6. History of epilepsy

          7. Unable or unwilling to commit to study treatment schedule

          8. Pregnant, or possible pregnancy planned for the duration of the study period

          9. Active skin disease of the lower legs (dermatitis, cellulitis, eczema, trauma)

         10. Documented allergy to patch electrodes or their adhesive

         11. Abnormal sensory function of the lower limb

         12. Metallic implant within the lower limb
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St Josephs Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Blayne Welk</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

